Minisymposium: Covalent inhibitors in Drug Discovery
Some of the worlds most widely used drugs, e.g. acetylsalicylic acid, penicillins, omeprazole, clopidogrel, etc, are all based on covalent inhibition of the target enzyme. However, few drugs are designed to be covalent, and the pharmaceutical industry is still cautious for this mode-of-action due to an inherent risk of late stage idiosyncratic toxicology. In this workshop we gather industrial and academic experts to review state-of-the-art and shed some light on this perplexity. Please, take the chance to discuss your own project with the speakers during the day.
The organizing committee
Registration and Coffee
Covalent Kinase Inhibitor Drugs: The Future is Already Here
Tjeerd Barf, Acerta Pharma, Netherlands
Safety first: Covalent inhibitors from a safety perspective
Mickael Mogemark, Astra Zeneca, Sweden
Reversible covalent inhibitors of cathepsins
Lourdes Salvador Oden, Medivir, Sweden
Utilizing a covalent mechanism for target identification and development of a STAT3 inhibitor prodrug
Martin Johansson, Glactone Pharma Development, Sweden
Bioanalysis of a soft and highly reactive electrophile
Lars Hagberg, Aprea, Sweden
Thank you for helping us improve by filling out this brief evaluation form.